Machine learning for medicine
Small-molecule screens aimed at identifying therapeutic candidates traditionally search for molecules that affect one to several outputs at most, limiting discovery of true disease-modifying drugs. Theodoris et al. developed a machine-learning approach to identify small molecules that broadly correct gene networks dysregulated in a human induced pluripotent stem cell disease model of a common form of heart disease involving the aortic valve. Gene network correction by the most efficacious therapeutic candidate generalized to primary aortic valve cells derived from more than 20 patients with sporadic aortic valve disease and prevented aortic valve disease in vivo in a mouse model.
Science, this issue p. eabd0724
Determining the gene-regulatory networks that drive human disease allows the design of therapies that target the core disease mechanism rather than merely managing symptoms. However, small molecules used as therapeutic agents are traditionally screened for their effects on only one to several outputs at most, from which their predicted efficacy on the disease as a whole is extrapolated. In silico correlation of disease network dysregulation with pathways affected by molecules in surrogate cell types is limited by the relevance of the cell types used and by not directly testing compounds in patient cells.
In principle, mapping the architecture of the dysregulated network in disease-relevant cells differentiated from patient-derived induced pluripotent stem cells (iPSCs) and subsequent screening for small molecules that broadly correct the abnormal gene network could overcome this obstacle. Specifically, targeting normalization of the core regulatory elements that drive the disease process, rather than correction of peripheral downstream effectors that may not be disease modifying, would have the greatest likelihood of therapeutic success. We previously demonstrated that haploinsufficiency of NOTCH1 can cause calcific aortic valve disease (CAVD), the third most common form of heart disease, and that the underlying mechanism involves derepression of osteoblast-like gene networks in cardiac valve cells. There is no medical therapy for CAVD, and in the United States alone, >100,000 surgical valve replacements are performed annually to relieve obstruction of blood flow from the heart. Many of these occur in the setting of a congenital aortic valve anomaly present in 1 to 2% of the population in which the aortic valve has two leaflets (bicuspid) rather than the normal three leaflets (tricuspid). Bicuspid valves in humans can also be caused by NOTCH1 mutations and predispose to early and more aggressive calcification in adulthood. Given that valve calcification progresses with age, a medical therapy that could slow or even arrest progression would have tremendous impact.
We developed a machine-learning approach to identify small molecules that sufficiently corrected gene network dysregulation in NOTCH1-haploinsufficient human iPSC-derived endothelial cells (ECs) such that they classified similar to NOTCH1+/+ ECs derived from gene-corrected isogenic iPSCs. We screened 1595 small molecules for their effect on a signature of 119 genes representative of key regulatory nodes and peripheral genes from varied regions of the inferred NOTCH1-dependent network, assayed by targeted RNA sequencing (RNA-seq). Overall, eight molecules were validated to sufficiently correct the network signature such that NOTCH1+/ ECs classified as NOTCH1+/+ by the trained machine-learning algorithm. Of these, XCT790, an inverse agonist of estrogen-related receptor (ERR), had the strongest restorative effect on the key regulatory nodes SOX7 and TCF4 and on the network as a whole, as shown by full transcriptome RNA-seq.
Gene network correction by XCT790 generalized to human primary aortic valve ECs derived from explanted valves from >20 patients with nonfamilial CAVD. XCT790 was effective in broadly restoring dysregulated genes toward the normal state in both calcified tricuspid and bicuspid valves, including the key regulatory nodes SOX7 and TCF4.
Furthermore, XCT790 was sufficient to prevent as well as treat already established aortic valve disease in vivo in a mouse model of Notch1 haploinsufficiency on a telomere-shortened background. XCT790 significantly reduced aortic valve thickness, the extent of calcification, and echocardiographic signs of valve stenosis in vivo. XCT790 also reduced the percentage of aortic valve cells expressing the osteoblast transcriptional regulator RUNX2, indicating a reduction in the osteogenic cell fate switch underlying CAVD. Whole-transcriptome RNA-seq in treated aortic valves showed that XCT790 broadly corrected the genes dysregulated in Notch1-haploinsufficient mice with shortened telomeres, and that treatment of diseased aortic valves promoted clustering of the transcriptome with that of healthy aortic valves.
Network-based screening that leverages iPSC and machine-learning technologies is an effective strategy to discover molecules with broadly restorative effects on gene networks dysregulated in human disease that can be validated in vivo. XCT790 represents an entry point for developing a much-needed medical therapy for calcification of the aortic valve, which may also affect the highly related and associated calcification of blood vessels. Given the efficacy of XCT790 in limiting valve thickening, the potential for XCT790 to alter the progression of childhood, and perhaps even fetal, valve stenosis also warrants further study. Application of this strategy to other human models of disease may increase the likelihood of identifying disease-modifying candidate therapies that are successful in vivo.
A gene networkbased screening approach leveraging human disease-specific iPSCs and machine learning identified a therapeutic candidate, XCT790, which corrected the network dysregulation in genetically defined iPSC-derived endothelial cells and primary aortic valve endothelial cells from >20 patients with sporadic aortic valve disease. XCT790 was also effective in preventing and treating a mouse model of aortic valve disease.
Mapping the gene-regulatory networks dysregulated in human disease would allow the design of network-correcting therapies that treat the core disease mechanism. However, small molecules are traditionally screened for their effects on one to several outputs at most, biasing discovery and limiting the likelihood of true disease-modifying drug candidates. Here, we developed a machine-learning approach to identify small molecules that broadly correct gene networks dysregulated in a human induced pluripotent stem cell (iPSC) disease model of a common form of heart disease involving the aortic valve (AV). Gene network correction by the most efficacious therapeutic candidate, XCT790, generalized to patient-derived primary AV cells and was sufficient to prevent and treat AV disease in vivo in a mouse model. This strategy, made feasible by human iPSC technology, network analysis, and machine learning, may represent an effective path for drug discovery.
Excerpt from:
Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease - Science
- The Firsthand Results Of A Nanofat Treatment Using Stem Cells And PRP - Forbes - November 16th, 2024
- Eat These 5 Underrated Foods To Boost Metabolism, Says An MD - mindbodygreen - November 16th, 2024
- BioRestorative Therapies IFATS 2024 Presentation to - GlobeNewswire - September 21st, 2024
- Fasting may help improve immune system; 3 reasons why one should fast at least once a week or a month - Times Now - February 24th, 2023
- Alpilean Weight Loss Reviews (Legit Or Fake) Dont Try Alpine Ice Hack Diet Before You See This! - Outlook India - February 24th, 2023
- Stevens Institute of Technology Professors Use Interdisciplinary Collaboration to Enhance the Field of 3D-Printed Tissues - India Education Diary - February 24th, 2023
- Stress can throw off circadian rhythms and lead to weight gain - Medical News Today - August 19th, 2022
- Scientists Aim to Bring the Tasmanian Tiger Back From Extinction Mother Jones - Mother Jones - August 19th, 2022
- Benefits Of Ozone Therapy In Pain Medicine - Nation World News - August 19th, 2022
- New Discovered Adipokines Associated with the Pathogenesis of Obesity | DMSO - Dove Medical Press - August 11th, 2022
- Slimvance Reviews - Does This Fat Burner Really Work? - Outlook India - August 11th, 2022
- Mesenchymal stem cells - PubMed - June 16th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - June 16th, 2022
- Fat Cells - The Definitive Guide | Biology Dictionary - June 16th, 2022
- Stem Cells For Back Pain | Stem Cells For Herniated Discs - June 16th, 2022
- 2022-06-13 | OTCPK:BRTXD | Press Release | BioRestorative Therapies - Stockhouse - June 16th, 2022
- Hepatic Diseases and Associated Glucose Intolerance | DMSO - Dove Medical Press - June 16th, 2022
- Why Fitness Experts Are Obsessed With "Bulletproofing" the Body - InsideHook - June 16th, 2022
- New Stem cell conveying hydrogel could assist the heart with recuperating myocardial ischemia - Microbioz India - August 17th, 2021
- Participants Diagnosis Halts Gene Therapy Clinical Trial - The Scientist - August 17th, 2021
- The Involuted Palate, or the Savage Crinkle of Future Snacks - lareviewofbooks - August 17th, 2021
- Time to Go Sushi With Cellular Salmon; When Pet Owners Tire of Their Minions - The SandPaper - August 17th, 2021
- Adipose-derived Stem Cell Market Analysis, Key Company Profiles, Types, Applications and Forecast To 2027 The Courier - The Courier - May 27th, 2021
- Global Cell Therapy Markets, Technologies, and Competitive Landscape Report 2020-2030: Applications, Cardiovascular Disorders, Cancer, Neurological... - May 27th, 2021
- What is lab grown meat? A scientist explains the taste, production and safety of artificial foods - BBC Focus Magazine - May 27th, 2021
- Rheumatoid Arthritis Stem Cell Therapy Market share, growth drivers, demand, supply, challenges, and investment opportunities by 2028 - WhaTech - May 27th, 2021
- Obesity-Related Inflammation and Endothelial Dysfunction in COVID-19: | JIR - Dove Medical Press - May 27th, 2021
- The hunt for the master cow that will feed the world - Wired.co.uk - May 27th, 2021
- Australia's Magic Valley On How to Turn Cells From "Cell Volunteer" Lucy the Lamb Into Lamb Steaks and Chops - vegconomist - the vegan... - May 27th, 2021
- Clearing Cellular Dead Wood | In the Pipeline - Science Magazine - May 27th, 2021
- University of Pittsburgh Won't Explain its Planned Parenthood Ties | Opinion - Newsweek - May 27th, 2021
- Smart Stem Cells Made From Fat Have the Power to Heal - Freethink - February 14th, 2021
- Their Goal: Meat That's Better Than Meat | Tufts Now - Tufts Now - January 31st, 2021
- Gut microbiota: How does it interact with the brain? - Medical News Today - December 30th, 2020
- The 10 Best Herbs for Liver Health: Benefits and Precautions - Healthline - December 19th, 2020
- Startups are racing to reproduce breast milk in the lab - MIT Technology Review - December 19th, 2020
- The facts about the danger of melanoma - The Hudson Reporter - December 19th, 2020
- And Now, a Moment for Culture(d Meat) - The Spoon - December 4th, 2020
- How to live longer: Calorie restriction may reset your biological body clock - Express - December 4th, 2020
- Future Meat is cutting costs on mass production with an unlikely cellular approach - The Spoon - November 30th, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization - OrthoSpineNews - November 25th, 2020
- The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser - November 7th, 2020
- Global Cell Therapy Technologies, Competitive Landscape & Markets, 2019-2020 & Forecast to 2029 - ResearchAndMarkets.com - Yahoo Finance - November 7th, 2020
- Blocking energy pathway reduces GVHD while retaining anti-cancer effects of T-cells - Science Codex - November 7th, 2020
- Singapore startup Shiok Meats re-creates shrimp in the lab - Los Angeles Times - October 10th, 2020
- Aqua-Spark Announces an Investment in Singapore-based Shiok Meats, the First Cell-Based Company to Produce Clean, Sustainable, Cruelty-Free Shrimp and... - October 6th, 2020
- Orgenesis to acquire regenerative medicine company Koligo Therapeutics - Pharmaceutical Business Review - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell Therapies - GlobeNewswire - September 30th, 2020
- Bariatric surgery is booming, as obese patients worry about their Covid-19 risks - The Daily Briefing - September 30th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Unica News - September 30th, 2020
- Regenerative medicine and war: The next breakthrough in treating injured veterans? - Genetic Literacy Project - September 29th, 2020
- Sherrie Hewson celebrates 70th birthday with second face lift to transform her looks - The Sun - September 15th, 2020
- Two Austin Women Hope to Build the First Lab-Grown Brisket - Texas Monthly - September 15th, 2020
- FDA Clears Jointechlabs' MiniTC for Point-of-Care Fat Tissue Processing and its Broad Range of Applications - PRNewswire - August 26th, 2020
- Photos That Reveal the Hidden Side of Things - Obsev - August 26th, 2020
- Research Roundup: Lasting Immunity to COVID-19 and More - BioSpace - August 25th, 2020
- The Truth About Cosmetic Treatments review a format in need of a facelift - The Guardian - August 25th, 2020
- Survivors of Pediatric Cancers May Experience Lasting Impact on Heart, Metabolic Health Following Radiation Therapy - Pharmacy Times - August 15th, 2020
- AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire - August 15th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Good Night, Good Hockey - August 15th, 2020
- Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media - August 15th, 2020
- Meat-lover who wants to save the planet? 3D printed steaks are your solution - ThePrint - July 12th, 2020
- Fat stem cells improve prognosis in patients with Covid-19 ... - July 11th, 2020
- Making Sense of Stem Cells and Fat Grafting in Plastic ... - July 11th, 2020
- Tip Sheet: SARS-CoV-2 antibodies, COVID-19 and health disparities, eating in tough times and immune protection in breast milk - Fred Hutch News... - July 9th, 2020
- Blood factors transfer beneficial effects of exercise on neurogenesis and cognition to the aged brain - Science Magazine - July 9th, 2020
- Fasting is not starvation or a fad, it is a discipline: Luke Coutinho - The Indian Express - July 9th, 2020
- Is Meat Grown in a Lab Really Meat? - The New York Times - July 7th, 2020
- What if mammoths are brought back from extinction? - The Economist - July 7th, 2020
- Cancer Stem Cells (CSCs) Market Recent Industry Developments and Growth Strategies Adopted by Players - Cole of Duty - July 1st, 2020
- Coronavirus symptoms: How COVID-19 can damage the brain - what to look for - Express - July 1st, 2020
- Westerleigh resident is alive because of stem cell therapy by his doctor -- for free. Heres his story. - SILive.com - June 13th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 13th, 2020
- Fat cells remember their diets early in life - Massive Science - June 13th, 2020
- Patient uses fat stem cells to repair his wrist - CNN - June 10th, 2020
- FDA Warns About Stem Cell Therapies | FDA - June 10th, 2020
- Regenerative Therapies: Helping Horses Self-Heal The Horse - TheHorse.com - May 31st, 2020
- AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -... - May 31st, 2020
- Hair regeneration using stem cells to treat baldness - BioNews - May 27th, 2020